Monitoring Heparin Therapy by the Activated Partial Thromboplastin Time - The Effect of Pre-Analytical Conditions

Summary

Blood and plasma specimens from patients receiving heparin were collected and stored under various conditions. The effect of these conditions on the activated partial thromboplastin time (APTT) was assessed. Four APTT reagents were used. Blood samples centrifuged at 600 × g gave slightly shorter APTTs than samples centrifuged at 940 × g and 2200 × g. Storage of uncentrifuged citrated-blood at room temperature resulted in 15-29% shortening of the APTT, depending on the reagent used. Storage of the same blood samples at 4° C resulted in 6-19% lengthening of the APTT. The presence of HEPES-buffer in citrated-blood shortened the APTT of heparinized patient specimens, but not of normal specimens. When blood was collected in a mixture of citric acid, theophylline, adenosine and dipyridamole (CTAD-mix-ture), storage at room temperature induced 0-11% decrease of the APTT, depending on the reagent used. Storage of CTAD-blood at 4° C resulted in 7-19% lengthening of the APTT. Shortening of the APTT could be explained by release of platelet factor 4 (PF4). Release of PF4 could be inhibited by CTAD-mixture. These data suggest that storage of CTAD-blood at room temperature is the best pre-analytical condition for reliable monitoring of heparin therapy by the APTT.

Keywords

Heparin monitoring - Activated partial thromboplastin time - Pre-analytical conditions - Platelet factor 4 - Anticoagulant for blood collection

• References

• 1 Banez EI, Triplett DA, Koepke J. Laboratory monitoring of heparin therapy. The effect of different salts of heparin on the activated partial thromboplastin time. An analysis of the 1978 and 1979 CAP Hematology Survey. Am J Clin Pathol 1980; 74: 569-574
• 2 Gilmer PR. Preanalytical variables in coagulation testing. In: Standardization of Coagulation Assays. An Overview. Triplett DA. (Ed), pp 1-8 College of American Pathologists; Skokie, Illinois: 1982
• 3 Koepke JA, Rodgers JL, Olliver MJ. Pre-instrumental variables in coagulation testing. Am J Clin Pathol 1975; 64: 591-596
• 4 Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. Am J Clin Pathol 1961; 36: 212-219
• 5 Thomson JM, Easton AC, Faragher EB. The use of vacutainer tubes for collection and storage of blood for coagulation testing. Clin lab Haemat 1983; 5: 413-421
• 6 Thomson JM. Specimen collection for blood coagulation testing. In: Laboratory Hematology. Koepke JA. (Ed), pp 833-863 Churchill Livingstone; New York: 1984
• 7 Putten JJ van, Ruit Mvan de, Beunis M, Hemker HC. Heparin neutralization during collection and processing of blood inhibited by pyridoxal 5¹-phosphate. Haemostasis 1984; 14: 253-261
• 8 Heyns Adu P, Berg DJ van den, Kleynhans P HT, du Toit PW. Unsuitability of evacuated tubes for monitoring heparin therapy by activated partial thromboplastin time. J Clin Pathol 1981; 34: 63-68
• 9 Huseby RM, Shafer D. Variables and questions related to a recent comparative heparin response evaluation (letter). Am J Clin Path 1978; 69: 99-100
• 10 Contant G, Gouault-Heilmann M, Martinoli JL. Heparin inactivation during blood storage: its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole - C.T.A. D. Mixture -. Tromb Res 1983; 31: 365-374
• 11 Levine SP, Sorenson RR, Harris MA, Knieriem LK. The effect of platelet factor 4 (PF4) on assays of plasma heparin. Br J Haematol 1984; 57: 585-596
• 12 O’Brien PF. The chromogenic assay of low levels of heparin in plasma: probable effect of platelets. Thromb Haemostas 1980; 43: 69
• 13 Hirsh J, Bishop J, Johnson M, Walker C. The development of antiheparin activity in stored vacutainer tubes. Blood 1976; 48: 1004
• 14 Houbouyan LL, Roussi JH, Goguel AF. Effect antihéparine dans les tubes “BD Vacutainer”. La Nouv Presse Med 1978; 7: 3262
• 15 O’Brien JR, Etherington MD, Pashley M. Intra-platelet platelet factor 4 (IP, PF4) and the heparin-mobilisable pool of PF4 in health and atherosclerosis. Thromb Haemostas 1984; 51: 354-357
• 16 Turi DC, Peerschke EI. Sensitivity of three activated partial thromboplastin time reagents to coagulation factor deficiencies. Am J Clin Pathol 1986; 85: 43-49
• 17 Stevenson KJ, Easton AC, Curry A, Thomson JM, Poller L. The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure. Thromb Haemostas 1986; 55: 250-258
• 18 Bolton AE, Ludlam CA, Pepper DS, Moore S, Cash JD. A radioimmunoassay for platelet factor 4. Thromb Res 1976; 8: 51-58
• 19 Stibbe J, Hemker HC, Van Creveld S. The inactivation of factor VIII in vitro. Thrombos Diathes Haemorrh 1972; 27: 43-58
• 20 Bowie E JW, Thompson JH, Owen CA. The stability of antihemophilic globulin and labile factor in human blood. Mayo Clin. Proc. 1964; 39: 144-151
• 21 Hemker HC, Kahn M JP. Studies on blood coagulation factor V. The inactivation of factor V and prothrombinase. Thrombos Diathes Haemorrh 1972; 27: 33-42
• 22 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-327
• 23 Roberts PS, Hughes HN, Fleming PB. The effects of hepes buffer on clotting tests, assay of factors V and VIII and on the hydrolysis of esters by thrombin and thrombokinase. Tromb Haemostas 1976; 35: 202-210
• 24 Godfrey R, Rhymes IL, Bidwell E, Barrowcliffe TW. The buffering of anticoagulants for blood collection. Thromb Diathes Haemorrh 1975; 34: 879-882
• 25 Van den Besselaar A MH P, Van Halem-Visser LP, Loeliger EA. The use of evacuated tubes for blood collection in oral anticoagulant control. Thromb Haemostas 1983; 50: 676-677